{"entity":{"id":"nct06220838","kind":"trial","name":"Study SC-101 in Subjects With Advanced Malignancies","aka":[],"tldr":"A phase 1 trial of SC-101 run by Tianjin ConjuStar Biologics Co., Ltd., now recruiting.","summary":"Study SC-101 in Subjects With Advanced Malignancies is a phase 1 interventional study registered as NCT06220838 by Tianjin ConjuStar Biologics Co., Ltd., with 100 participants planned, started 2024-02-02. Conditions recorded: Advanced Solid Tumor. Interventions recorded: SC-101.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06220838","url":"https://clinicaltrials.gov/study/NCT06220838"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sc-101"],"companies":["conjustar-biologics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06220838","phase":"1","setting":"A Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-101 in Subjects With Advanced or Metastatic Solid Tumors That Express Nectin-4","sponsor":"Tianjin ConjuStar Biologics Co., Ltd.","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06220838/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"sc-101","kind":"drug","name":"SC-101","route":"/drugs/sc-101/"}],"company":[{"id":"conjustar-biologics","kind":"company","name":"ConjuStar Biologics","route":"/companies/conjustar-biologics/"}]}}